[CARD study: relevance for the treatment of advanced prostate cancer].

CONCLUSION: In mCRPC patients eligible for chemotherapy, the therapy sequence should be chosen so that the patients also receive cabazitaxel. A direct therapy sequence with two ARTAs should be avoided or, at least, only considered if other substances are contraindicated.
PMID: 32968994 [PubMed - as supplied by publisher]

Source: Aktuelle Urologie - September 22, 2020 Category: Urology & Nephrology Authors: Merseburger AS, Bannowsky A, Becker K, Bokemeyer C, Eichenauer R, Lehmann J, Mickisch G, Steuber T, von Amsberg G, von Kügelgen T, Wülfing C Tags: Aktuelle Urol Source Type: research